Healthy Volunteers Clinical Trial
Official title:
Evaluation of Vitamin A Absorption From Fortified Bouillon Using Post-prandial Retinyl Ester Response in Comparison With an Oil-based Vitamin A Supplement
The goal of this clinical trial is to measure how well different formulations of vitamin A (VA) are absorbed by the body when they are added to bouillon (broth) as vitamin A palmitate (VAP). Fortifying bouillon cubes with VA is one potential approach to addressing VA deficiency, which is a major public health issue in many low- and lower-income countries. The main question this study aims to answer is to compare the amount of VA that is absorbed by the body from three different VAP formulations that are added to bouillon. Participants will consume different formulations of VA and have multiple blood collections.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 49 Years |
Eligibility | Inclusion Criteria: - Healthy, nonpregnant women - =18 and <49 years of age - Able and willing to provide informed consent - Body mass index (BMI) between 20 to 30 kg/m2 - Willing and able to undergo study procedures, including: repeated blood sampling, a baseline hemoglobin and pregnancy test, adherence to a low-vitamin A diet at specified times throughout the study, consumption of provided meals (specifically, a breakfast of bouillon, peanut butter, and a bagel or bread), and, except for the Screening visit, foregoing alcohol for at least 2 days before each visit and fasting for =8 hours before each visit Exclusion Criteria: - Currently pregnant - Breastfeeding a child under 1 year of age - Allergic to soy or peanut butter - Current use of smoking tobacco products or any other form of nicotine - Active eating disorder diagnosis - Current diagnosis of acute or chronic illness, including hepatitis, Celiac's disease, Crohn's disease, and cystic fibrosis - Moderate or severe anemia according to World Health Organization guidelines (i.e., hemoglobin =10.9 g/dL) - Unable or unwilling to refrain from consuming alcohol when required - Unable or unwilling to discontinue consumption of foods that are high in vitamin A and of vitamin A supplements when required during the study - Taking prescription oral medication that includes a retinoid, e.g., isotretinoin/ Accutane - Taking proton pump inhibitors. - Unable/unwilling to avoid taking antacids during the fasting period prior to sample collection - Unable/unwilling to fast for periods of at least 10 hours at a time - Status relationship with a member of the study team. - Unable to fulfill study requirements per the judgment of the investigator |
Country | Name | City | State |
---|---|---|---|
United States | University of Wisconsin-Madison | Madison | Wisconsin |
Zambia | Tropical Diseases Research Centre | Ndola | |
Zambia | Tropical Diseases Research Centre - Field Office | Rufunsa |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Madison | Particles for Humanity, PBC, Tropical Diseases Research Centre, Zambia |
United States, Zambia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Total body vitamin A using retinol isotope dilution | The retinol isotope dilution test provides an estimate of total body stores of vitamin A, (umol) | Baseline | |
Other | Liver vitamin A concentrations using retinol isotope dilution | The retinol isotope dilution test provides an estimate of liver vitamin A concentrations, (umol/g) | Baseline | |
Other | C-reactive protein | To determine inflammation at each treatment visit, (mg/L) | Baseline | |
Other | Serum carotenoids | Serum carotenoid concentrations will be measured using high-performance liquid chromatography at baseline for each treatment visit, (nmol/L) | Baseline | |
Primary | Serum retinyl ester area-under-the-effect-curve | The serum retinyl ester area-under-the-effect-curve (corrected for baseline retinyl ester concentrations) will be calculated for each treatment to determine relative absorption of vitamin A, (nmol/L*h) | Baseline to 8 hours | |
Primary | Serum retinyl ester area-under-the-effect-curve | The serum retinyl ester area-under-the-effect-curve (corrected for baseline retinyl ester concentrations) will be calculated for each treatment to determine relative absorption of vitamin A, (nmol/L*h) | Baseline to 24 hours | |
Secondary | Serum retinol maximum concentration (Cmax) | Maximum serum retinol concentration observed, (µmol/L) | Baseline to 24 hours | |
Secondary | Serum retinyl ester maximum concentration (Cmax) | Maximum serum retinyl ester concentration observed, (nmol/L) | Baseline to 24 hours | |
Secondary | Time to maximum serum retinol concentration (Tmax) | Time to maximum serum retinol concentration, (h) | Baseline to 24 hours | |
Secondary | Time to serum retinyl ester maximum concentration (Tmax) | Time to maximum serum retinyl ester concentration, (h) | Baseline to 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |